- Home
- HGV vs SLNO Comparison
HGV vs SLNO Comparison
Compare HGV & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGV
- SLNO
- Stock Information
- Founded
- HGV 1992
- SLNO 1999
- Country
- HGV United States
- SLNO United States
- Employees
- HGV N/A
- SLNO N/A
- Industry
- HGV Hotels/Resorts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- HGV Consumer Discretionary
- SLNO Health Care
- Exchange
- HGV Nasdaq
- SLNO Nasdaq
- Market Cap
- HGV 4.0B
- SLNO 3.8B
- IPO Year
- HGV N/A
- SLNO 2014
- Fundamental
- Price
- HGV $47.11
- SLNO $69.77
- Analyst Decision
- HGV Buy
- SLNO Strong Buy
- Analyst Count
- HGV 7
- SLNO 10
- Target Price
- HGV $51.29
- SLNO $112.50
- AVG Volume (30 Days)
- HGV 1.1M
- SLNO 1.6M
- Earning Date
- HGV 07-31-2025
- SLNO 11-05-2025
- Dividend Yield
- HGV N/A
- SLNO N/A
- EPS Growth
- HGV N/A
- SLNO N/A
- EPS
- HGV 0.57
- SLNO N/A
- Revenue
- HGV $4,478,000,000.00
- SLNO $32,656,999.00
- Revenue This Year
- HGV $15.79
- SLNO N/A
- Revenue Next Year
- HGV $8.63
- SLNO $175.39
- P/E Ratio
- HGV $84.09
- SLNO N/A
- Revenue Growth
- HGV 12.43
- SLNO N/A
- 52 Week Low
- HGV $30.59
- SLNO $41.50
- 52 Week High
- HGV $52.08
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- HGV 54.58
- SLNO 42.02
- Support Level
- HGV $46.23
- SLNO $65.85
- Resistance Level
- HGV $47.94
- SLNO $70.12
- Average True Range (ATR)
- HGV 1.14
- SLNO 2.55
- MACD
- HGV 0.21
- SLNO 0.27
- Stochastic Oscillator
- HGV 72.77
- SLNO 63.97
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.